Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pulling iclaprim out of the ashes

This article was originally published in Scrip

Executive Summary

Seven years ago, the antibiotic iclaprim looked dead in the water. Seven months ago, Motif Bio was barely a blip on the biotech radar. But seven years is a long time in the antibiotic space, and seven months is a long time in biotech. Things are looking very different for both iclaprim and Motif. Scrip met with CEO Graham Lumsden, formerly of Merck & Co, and chairman Richard Morgan, CEO of majority shareholder Amphion Innovations, to get the details.

You may also be interested in...



Motif Bio Poised For Filings As Iclaprim Succeeds Again In Phase III

Positive data from a second Phase III trial sets up Motif Bio for an NDA filing by the end of the year for novel antibiotic iclaprim – but success for the product has been a long time coming.

Motif A Step Closer To Succeeding With Iclaprim After Phase III Success

Biotech firm hopes its once-shelved antibiotic will provide a therapeutic option for renally impaired patients with serious skin infections. With only one previous DHFR inhibitor ever approved, Motif also anticipates that iclaprim will offer an option for multidrug-resistant infections.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC028937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel